Assessment of two prophylactic fluid strategies in aneurysmal subarachnoid hemorrhage: A randomized trial.
Aneurysmal subarachnoid hemorrhage
Barthel’s index
Glasgow outcome score
cerebral vasospasm
euvolemic
hydroxyethyl starch
prophylactic fluid strategy
Journal
The Journal of international medical research
ISSN: 1473-2300
Titre abrégé: J Int Med Res
Pays: England
ID NLM: 0346411
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
entrez:
22
7
2020
pubmed:
22
7
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
To compare the effect of two prophylactic euvolemic fluid strategy regimens on the incidence of cerebral vasospasm and clinical outcomes in patients with aneurysmal subarachnoid hemorrhage (SAH). Ninety-six patients with a basal intravenous intake of 15 mL/kg/day of Ringer's lactate solution were included, and an additional 15 to 50 mL/kg/day Ringer's lactate (RL-group) or hydroxyethyl starch 130/0.4 solution (HES-group) was administered to maintain the targeted mean arterial pressure. The primary end point was the occurrence of cerebral vasospasm during the first 14 days. The secondary end points were case fatality, Barthel's index, and Glasgow Outcome Scores (GOS) at 30 days after SAH. Cerebral vasospasm developed in 42 patients (43.7%), and nine of these events were severe. The vasospasm rate among the RL- and HES-based groups was 25/48 and 17/48, respectively. For the secondary endpoint, four patients (4%) died by the end of follow-up (two in each group). Unfavorable outcome cases were not different in the RL and HES groups (9 vs. 14, respectively). There was no difference between the Barthel's scores at 30 days between the two groups. Using starches in a prophylactic treatment strategy in aneurysmal SAH in not supported by the study.The trial was registered at Clinicaltrials.gov under the number NCT02064075.
Identifiants
pubmed: 32689849
doi: 10.1177/0300060520927526
pmc: PMC7375726
doi:
Banques de données
ClinicalTrials.gov
['NCT02064075']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
300060520927526Références
Neurocrit Care. 2011 Feb;14(1):24-36
pubmed: 20838932
Stroke. 2000 Feb;31(2):383-91
pubmed: 10657410
Neurocrit Care. 2014 Dec;21(3):462-9
pubmed: 24865266
Neurocrit Care. 2006;4(1):68-76
pubmed: 16498198
J Stroke Cerebrovasc Dis. 2015 Oct;24(10):2245-51
pubmed: 26277290
Neurocrit Care. 2011 Sep;15(2):211-40
pubmed: 21773873
J Neurosurg. 2003 May;98(5):978-84
pubmed: 12744357
Curr Treat Options Neurol. 2005 Mar;7(2):99-107
pubmed: 15676113
Neurocrit Care. 2013 Oct;19(2):140-9
pubmed: 23715669
Stroke. 1997 Mar;28(3):660-4
pubmed: 9056628
Neurosurgery. 1984 Sep;15(3):354-61
pubmed: 6483150
Neurosurgery. 2001 Sep;49(3):593-605; discussion 605-6
pubmed: 11523669
Stroke. 1987 Mar-Apr;18(2):365-72
pubmed: 3564092
Stroke. 2010 Oct;41(10):2391-5
pubmed: 20798370
Semin Respir Crit Care Med. 2017 Dec;38(6):760-767
pubmed: 29262433
Neurocrit Care. 2013 Oct;19(2):137-9
pubmed: 24022830
Neurocrit Care. 2012 Oct;17(2):191-8
pubmed: 21688008
Lancet. 1977 Nov 5;2(8045):941-3
pubmed: 72286
Neurosurgery. 1982 Sep;11(3):337-43
pubmed: 7133349
Ann Neurol. 1985 Aug;18(2):211-6
pubmed: 4037761
PLoS One. 2018 Feb 15;13(2):e0192832
pubmed: 29447255